Cytokinetics, Inc. — Q2 2014 Form 10-Q
Business context and reporting period
Clinical-stage biopharmaceutical company developing small-molecule therapies that modulate muscle function. The filing covers the quarter and six months ended June 30, 2014; balance-sheet figures are as of June 30, 2014. Its clinical-stage candidates are tirasemtiv (ALS and other neuromuscular disorders), CK-2127107 (skeletal muscle weakness, partnered with Astellas), and omecamtiv mecarbil (heart failure, partnered with Amgen). The company has no commercial product sales.
Financial performance and liquidity
| Metric | Q2 2014 | Q2 2013 | Six months 2014 | Six months 2013 |
|---|---|---|---|---|
| Revenue | $7.8 million | $1.0 million | $15.8 million | $1.8 million |
| Operating expenses | $16.2 million | $16.1 million | $32.9 million | $29.5 million |
| Operating loss | $8.4 million | $15.1 million | $17.2 million | $27.7 million |
| Net loss | $8.4 million | $15.0 million | $17.1 million | $27.7 million |
| Net loss per share | $0.23 | $0.58 | $0.49 | $1.11 |
Revenue growth primarily reflected Astellas collaboration reimbursements, milestone revenue, and recognition of its upfront license fee. R&D spending rose 9% for the first half, to $24.2 million; G&A rose 18%, to $8.7 million. No gross margin is reported; commercial product revenue has not begun.
Cash, cash equivalents and investments totaled $92.1 million at June 30, versus $80.2 million at December 31, 2013. Cash and cash equivalents alone were $12.4 million; short- and long-term investments were $65.4 million and $14.4 million. First-half operating cash use was $27.2 million, investing cash use $20.4 million, and financing cash provided $39.8 million, including $37.5 million net proceeds from a February equity offering. The filing reports no borrowings on the balance sheet; operating lease commitments totaled $14.4 million through 2018. Current assets were $80.1 million and current liabilities $16.9 million.
Material changes and operating developments
- Compared with the prior-year periods, revenue increased sharply while net losses narrowed, primarily reflecting collaboration-related revenue rather than product sales. First-half operating expenses increased despite lower Q2 R&D expense.
- Common shares outstanding increased from 30.7 million at year-end 2013 to 36.6 million at June 30, 2014, principally reflecting the February offering. Approximately 6.7 million warrants were also outstanding at quarter-end.
- BENEFIT-ALS, a Phase IIb tirasemtiv trial, missed its primary endpoint (ALSFRS-R change: -2.98 versus -2.40 points for placebo; p=0.11). Tirasemtiv showed a statistically significant reduction in decline in slow vital capacity, but treatment was associated with more withdrawals and more dizziness, fatigue, nausea, and weight loss.
- CK-2127107 Phase I studies continued; enrollment in one study was completed during Q2. Amgen’s COSMIC-HF expansion study continued enrollment, and Cytokinetics began dosing the Japan-related omecamtiv mecarbil pharmacokinetic study.
Guidance, outlook, risks and unusual items
- Management forecast 2014 revenue of $29–31 million, R&D expense of $52–55 million, and G&A expense of $16–18 million.
- Management believed available cash, cash equivalents and investments would fund requirements for at least 12 months. The company expected continuing operating losses and cash outflows and noted that additional capital or collaboration funding may be needed; future financing may be unavailable or dilutive.
- BENEFIT-ALS results may inform further tirasemtiv development, but additional development requires significant funding. The company said it intended to seek damages from its data-management vendor over a programming error that caused 58 patients assigned to tirasemtiv to receive placebo for a portion of the trial.
- Key risks include clinical failure or delay, adverse events, dependence on Amgen and Astellas’ decisions and funding, inability to secure additional capital, manufacturing and regulatory challenges, and competition. The company reported no legal proceedings and no material change in internal controls; management said disclosure controls were effective.
Important facts for investors to verify
- Whether management’s 2014 revenue and expense ranges were achieved, and how much reported revenue represents recurring reimbursements versus upfront-fee recognition or milestones.
- Cash burn and runway relative to the stated 12-month funding assessment, including subsequent financing needs and potential dilution from shares and warrants.
- Further tirasemtiv analyses and development plans, particularly the significance and reproducibility of the SVC result given the missed primary endpoint and tolerability findings.
- Progress, costs, and partner commitments for CK-2127107 and omecamtiv mecarbil, including whether expected study milestones were met.
- Deferred collaboration revenue balances and recognition timing, and any outcome of the contemplated claim against the BENEFIT-ALS data-management vendor.